Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 62Neoplasm Metastasis 10Stomach Neoplasms 9Brain Neoplasms 6Neoplasms 4HER2-positive Breast Cancer 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms, Male 4Lung Neoplasms 3Inflammatory Breast Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Meningeal Carcinomatosis 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Central Nervous System Diseases 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Solid Cancer 1Sarcoma 1Recurrence 1Pathologic Processes 1Ovarian Neoplasms 1Nervous System Neoplasms 1Nervous System Diseases 1Neoplastic Processes 1

Interventions

Trastuzumab 1Paclitaxel 1HM781-36B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × HER-2 Positive Advanced Gastric Cancer × Trastuzumab × Clear all
NCT01746771 2016-03-03

A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

Hanmi Pharmaceutical Company Limited

Phase 1/2 Completed
44 enrolled
Gastrointestinal

HER-2 Positive Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡